Sleep Cycle AB (publ)

OM:SLEEP 주식 리포트

시가총액: SEK 310.7m

Sleep Cycle 향후 성장

Future 기준 점검 4/6

Sleep Cycle (는) 각각 연간 13.3% 및 10% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.7% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 28.2% 로 예상됩니다.

핵심 정보

13.3%

이익 성장률

-19.71%

EPS 성장률

Software 이익 성장35.0%
매출 성장률10.0%
향후 자기자본이익률28.17%
애널리스트 커버리지

Low

마지막 업데이트30 Apr 2026

최근 향후 성장 업데이트

Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery

Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).

SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential

Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.

SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside

Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.

SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside

Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.

SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside

Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.

These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts

Feb 09
These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts

Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53

Feb 07
Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53

SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play

Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).

SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside

Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.

SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside

Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).

There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings

Jan 04
There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings

SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential

Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.

Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%

Sep 09
Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%

Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.

Aug 27
Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.

Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities

Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.

Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%

Apr 29
The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%

Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00

Apr 08
Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
User avatar

Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships

Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.

Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's

Mar 06
Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's

Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year

Feb 10
Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year

Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model

Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device for

이익 및 매출 성장 예측

OM:SLEEP - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20282984746672
12/31/20272583848642
12/31/202621810-29162
3/31/2026236452243N/A
12/31/2025248534053N/A
9/30/2025257594959N/A
6/30/2025261625666N/A
3/31/2025263655562N/A
12/31/2024262636064N/A
9/30/2024256566063N/A
6/30/2024251556466N/A
3/31/2024243496569N/A
12/31/2023236464653N/A
9/30/2023229394050N/A
6/30/2023224333141N/A
3/31/2023218332737N/A
12/31/2022212345462N/A
9/30/2022206376470N/A
6/30/2022199346471N/A
3/31/2022191144955N/A
12/31/202118381420N/A
9/30/20211776813N/A
6/30/2021168121719N/A
3/31/2021163333536N/A
12/31/2020159444646N/A
12/31/201912342N/A48N/A
12/31/20189327N/A53N/A

애널리스트 향후 성장 전망

수입 대 저축률: SLEEP 의 연간 예상 수익 증가율(13.3%)이 saving rate(2%)보다 높습니다.

수익 vs 시장: SLEEP 의 연간 수익(13.3%)이 Swedish 시장(8.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: SLEEP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: SLEEP 의 수익(연간 10%)이 Swedish 시장(연간 0.07%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: SLEEP 의 수익(연간 10%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SLEEP의 자본 수익률은 3년 후 28.2%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/06 18:32
종가2026/05/06 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sleep Cycle AB (publ)는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Oscar ErixonCarnegie Investment Bank AB
Erik GranströmDNB Carnegie
Rikard EngbergDNB Carnegie Commissioned Research